UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May, 2026.

Commission File Number: 001-40530

GH Research PLC

(Exact name of registrant as specified in its charter)

Joshua Dawson House

Dawson Street

Dublin 2

D02 RY95

Ireland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

~~INFORMATION~~GH ~~CONTAINED~~Research INPLC ~~THIS~~(the ~~REPORT~~“Company”) ONwill ~~FORM~~attend ~~6-K~~the American Society of Clinical Psychopharmacology (“ASCP”) Annual Meeting, which is scheduled to take place from May 26 – 29, 2026, in Miami, Florida (the “Congress”).

OnThe ~~May 14, 2026, GH Research PLC (the “~~Company”) entered into an At-the-Market Equity Offering Sales Agreement (the “Sales Agreement”) with Stifel, Nicolaus & Company, Incorporated (the “Agent”) to offer and sell up to $200 million of ordinary shares (the “Shares”), nominal value $0.025 per share, from time to time through the Agent, acting as sales agent or principal. The Sales Agreement includes the terms and conditions for the offering and sale of the Shares, indemnification and contribution obligations, and other terms and conditions customary in agreements of this type. The sales, if any, of the Shares under the Sales Agreement will bepresent ~~made~~posters byduring ~~any method permitted by law deemed to be an “at~~ the ~~market~~Congress ~~offering”~~ as ~~defined~~part ~~in Rule 415(a)(4) promulgated under the Securities Act~~ of ~~1933,~~Poster asSession ~~amended (the “Securities Act”)~~I. The foregoing description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the Sales Agreement, which is attached to this Report on Form 6-K as Exhibit 1.1.

~~The~~A ~~offering~~copy ~~and sale~~ of the ~~Shares~~poster ~~has been registered under the Securities Act, pursuant~~ to abe ~~registration~~presented ~~statement~~by onRoger ~~Form F-3 (File No. 333-285310) (the “Registration Statement”). The Company has filed with the U.~~S. ~~Securities~~McIntyre and Exchange Commission a prospectus supplement dated May 14, 2026, together with an accompanying prospectus dated March 7, 2025, relating to the offer and sale of the Shares. Opinion of counsel regarding the validity of the Shares is attached tohereto ~~this Report on Form 6-K~~ as Exhibit 599.1 ~~and the applicable consent of such counsel relating to the incorporation of such opinion into the Registration Statement is attached to this Report on Form 6-K as Exhibit 23~~.1.

~~INCORPORATION~~A BYcopy ~~REFERENCE~~of the poster to be presented by Michael E. Thase is attached hereto as Exhibit 99.2.

~~This~~A ~~Report~~copy onof ~~Form~~the ~~6-K,~~poster ~~including Exhibits 1.1, 5.1 and 23.1, shall be deemed~~ to be ~~incorporated~~presented by ~~reference~~Wiesław ~~into the registration statements on Form S-8 (Registration Nos~~J. ~~333-270422,~~Cubała ~~333-285311 and 333-294036) and the registration statements on Form F-3 (Registration Nos. 333-285310 and 333-295872) of the Company and to be a part thereof from the date on which this report~~ is ~~filed,~~attached tohereto ~~the~~as ~~extent~~Exhibit ~~not superseded by documents or reports subsequently filed or furnished~~99.3.

Exhibit Index

Exhibit No.	Description
99.1	Poster presented by Roger S. McIntyre, with Title: Rapid and Sustained Improvement in Anhedonia Following Inhaled Mebufotenin (GH001) Treatment in Patients With Treatment-Resistant Depression
99.2	Poster presented by Michael E. Thase, with Title: GH001 Efficacy is Independent of Prior Antidepressant Treatment Failures in Treatment-Resistant Depression: A Post Hoc Analysis of a Phase 2b Randomized Controlled Trial
99.3	Poster presented by Wiesław J. Cubała, with Title: Impact of GH001 on Depressive Symptoms, Anxiety, and Quality of Life in Treatment-Resistant Depression: Results from a Phase 2b Trial

EXHIBIT INDEX

Exhibit No.	Description
1.1	At-the-Market Equity Offering Sales Agreement, dated May 14, 2026, between GH Research PLC and Stifel, Nicolaus & Company, Incorporated
5.1	Opinion of A&L Goodbody LLP, Irish counsel of GH Research PLC
23.1	Consent of A&L Goodbody LLP (included in Exhibit 5.1)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GH Research PLC
Date: May 14, 2026
Date: May 21, 2026
	By:	/s/ Julie Ryan
	Name:	Julie Ryan
	Title:	Vice President, Finance

Filing Compare · GH Research PLC